{"paper_id":"f325fe77-6c08-4199-aeca-735c5d899ce0","body_text":"original articles\nLi Chen, Lan Tang, Weiwei Dong, Shuhua Zeng, Sisi Wu, Hong Ye\nBackground: Endometriosis is a hormone-related gynecological disease and characterized by the invasion of endometrial cells outside the uterine cavity. Objective: This study aimed to investigate the impact of goserelin acetate implants on hormone levels in patients with endometriosis using a systematic review methodology. Methods: A comprehensive search of databases including PubMed, VIP, CNKI and Wanfang was conducted for controlled trials from 2000 to 2025. Results: 12 included trials (1,299 participants) showed that goserelin acetate implant treatment significantly improved endometriosis [OR: 5.82, 95% CI (3.20, 10.59), P<0.000001], increased luteinizing hormone [MD: -2.04, 95% CI (-2.26, -1.83), P<0.00001], follicle-stimulating hormone [MD: -2.34, 95% CI (-2.58, -2.10), P<0.00001] and estradiol levels [MD: -1.89, 95% CI (-2.11, -1.66), P<0.00001], while reducing Visual Analog Scale scores [MD: -0.41, 95% CI (-0.48, -0.34), P<0.000001], recurrence rates [OR: 0.15, 95% CI (0.09, 0.24), P<0.00001] and adverse reactions [OR: 0.19, 95% CI (0.06, 0.55), P<0.00001]. The funnel plot exhibited an inverted funnel shape with relative symmetry, indicating no significant publication bias. Conclusion: The study demonstrates that goserelin acetate implants can effectively enhance overall treatment outcomes and regulate hormone levels in endometriosis patients.\nEndometriosis\nGoserelin acetate implant\nHormone levels\nMeta-analysis","source_license":"public-domain-us","license_restricted":false}